William Blair Comments on Agenus’ Q3 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) – Analysts at William Blair dropped their Q3 2025 earnings per share (EPS) estimates for Agenus in a report issued on Tuesday, August 12th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings per share of ($0.98) for the quarter, down from their previous forecast of ($0.65). The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. William Blair also issued estimates for Agenus’ Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($4.06) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.62) EPS and FY2027 earnings at ($3.61) EPS.

Other equities research analysts have also recently issued research reports about the company. Robert W. Baird raised their target price on Agenus from $4.00 to $6.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 4th. Wall Street Zen raised Agenus from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Zacks Research upgraded Agenus to a “hold” rating in a research report on Tuesday. HC Wainwright upgraded Agenus from a “neutral” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Wednesday, June 4th. Finally, B. Riley restated a “buy” rating on shares of Agenus in a research report on Monday, April 21st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Agenus currently has an average rating of “Moderate Buy” and an average price target of $15.50.

Agenus Stock Up 1.8%

AGEN stock opened at $4.63 on Friday. The business has a fifty day moving average of $5.36 and a two-hundred day moving average of $3.70. The stock has a market cap of $147.51 million, a price-to-earnings ratio of -0.65 and a beta of 1.62. Agenus has a 52-week low of $1.38 and a 52-week high of $7.34.

Agenus (NASDAQ:AGEN) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.22). The business had revenue of $25.70 million during the quarter, compared to the consensus estimate of $49.71 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. B. Riley Financial Inc. purchased a new position in shares of Agenus during the fourth quarter worth $2,074,000. Siren L.L.C. purchased a new position in Agenus in the first quarter valued at $752,000. AQR Capital Management LLC boosted its holdings in Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after purchasing an additional 427,604 shares during the period. Marshall Wace LLP purchased a new position in Agenus in the second quarter valued at $1,976,000. Finally, Bank of America Corp DE boosted its holdings in Agenus by 110.0% in the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after purchasing an additional 220,327 shares during the period. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.